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ABSTRACT
Introduction: The objective of this study was to
document the initiation of insulin therapy in
patients with type 2 diabetes mellitus (T2DM)
and its maintenance as a function of time after
initiation in a French nationwide representative
cohort.
Methods: A retrospective cohort study was
conducted on a random sample of*600,000
beneficiaries registered in the French national
health insurance database. Newly insulin
treated T2DM patients were selected.
Persistence was defined as remaining on
insulin without discontinuation (defined over
a 6 or a 12-month period).
Results: Among 1909 initiations identified in
2012/2013 (basal scheme: 61.8%, basal/rapid:
15%, other schemes: 23.2%) the average age
(standard deviation) at initiation was,
respectively, 67.5 (14.2), 61.8 (18.1) and 63.2
(18.4) years. Insulin was initiated by general
practitioners in 39.3% and prescribed without
other antidiabetic drugs in 32.0%. Persistence
was studied in 1969 patients initiating insulin
in 2011/2012. Among survivors, nearly 25%
stopped insulin during the first year (18.4% for
basal scheme). Patients discontinuing insulin
were younger [64.7 years (18.5) vs 67.3 years
(14.3) p = 0.0003] and less often male (45.8% vs
55.7%, p\0.0001). A proportion of 20.2% did
not receive any antidiabetic drug over
12 months after discontinuation. These high
percentages were only partly explained by
transient intensive insulin regimens in acutely
ill patients identifiable in the database.
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Conclusion: We observed a high rate of early
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(but lower with basal insulin scheme). Further
real world studies are warranted to identify
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INTRODUCTION
Insulin treatment has historically been the
mainstay of the management of type 1
diabetes mellitus (T1DM), but has only more
recently come to occupy a central role in the
management of type 2 diabetes mellitus
(T2DM). This change has partly relied on the
introduction of modified long-acting insulins
(basal insulins) as well as blood glucose control
devices that make insulin therapy simpler for
the patient. In particular, insulin therapy is
recommended in patients who fail to achieve
glycemic control with combinations of oral
antidiabetic drugs (OADs) [1–3]. In USA, about
33.5% of patients aged 18 years or older with
prescribed treatment for diabetes are receiving
insulin therapy [4]. In France, it has been
estimated that only 25% of the three million
patients with prescribed treatment for diabetes
are treated with insulin [5].
Both T2DM and T1DM patients have
difficulties managing their antidiabetic
medications including insulin [6]. Among
T2DM patients, this often results in low
treatment persistence, which has been defined
as the proportion of patients who remained on
treatment for a specific time or the duration of
time from initiation to discontinuation of
therapy.
Treatment adherence and persistence are
important factors that influence the
effectiveness of antidiabetic medication [7–11]
and there is considerable evidence that
adherence to and persistence with OADs
remains suboptimal [11, 12].
A number of studies have been performed to
evaluate persistence in patients prescribed
OADs, but less in patients receiving insulin
therapy, although renouncement to insulin
leaves the patients with limited choice of
anti-diabetes therapy [13–17]. Most of these
studies were conducted in the US. The objective
of this study was to document the initiation of
insulin therapy in patients with T2DM and its
maintenance as a function of time after
initiation in a European nation-wide
representative cohort.
METHODS
This study was a retrospective analysis of a
sample of patients with T2DM documented in a
French national prescription claims database
[E´chantillon Ge´ne´raliste de Be´ne´ficiaires, (EGB)]
performed in 2014. The study included a
cross-sectional phase to document initiation of
insulin therapy, and a longitudinal phase to
document treatment persistence.
Data Source
The EGB database [18] represents a 1/97 random
sample of individuals selected from all
beneficiaries of the three main public health
insurance funds and provides data of around
600,000 individuals representative of the
French population. The sample of the general
population is renewed every 3 months, is
anonymous and is representative of healthcare
expenditure at the national level. The EGB
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database is updated every month. All
information in the database is anonymous.
The insurance funds contributing to the EGB
are the Caisse Nationale d’Assurance Maladie
des Travailleurs Salarie´s (CNAMTS), the
Mutualite´ Sociale Agricole (MSA) and the
Re´gime Social des Inde´pendants (RSI). The
CNAMTS is the French health insurance fund
for salaried workers, which includes all salaried
workers and their relatives and covers 77% of
the French population in 2011 (almost 50
million people). The MSA covers agricultural
workers and the RSI self-employed people.
Individuals remain covered by the same fund
if they stop working for any reason, including
retirement, unemployment, invalidity or
long-term sick leave. If nearly all the
population is covered with insurance funds in
France, 87% of the population covered is
considered in the EGB, as the information
system is different for some population
sub-groups mainly government workers and
students.
This database contains comprehensive
reimbursement records of all items of
community and hospital healthcare
consumption in the public or private sectors
eligible for reimbursement by public health
insurance. All eligible medical expenditure
reimbursed for a given individual is linked
through a unique patient identifier.
Documented expenditure includes
hospitalisations [identified by diagnosis-related
group (DRG)], consultations, paraclinical tests,
medical devices, medical procedures,
medication [identified by Anatomical
Therapeutic Chemical classification (ATC)],
auxiliary care (for example, nursing care and
physiotherapy) and healthcare transport. For
each prescribed or reimbursed service, the date
of implementation is specified, together with
the date of prescription and the healthcare
provider. No explicit information is provided
for the reason for which the service was
prescribed, for example, the diagnosis. No
sociodemographic information is available,
with the exception of age and gender. Items
which are not eligible for reimbursement, such
as over-the-counter drugs, are not documented
in the database and cannot be identified. In
addition, information on inpatient
rehabilitation is not available.
The only types of data in the EGB database
associated with an explicit diagnosis are
hospitalization and eligibility for full
insurance coverage due to a severe chronic
disease (Long-standing condition status). In
the case of hospitalisations, the diagnosis can
be identified since each hospital stay is valued
on the basis of a unique DRG which is coded
using the international classification of disease
(ICD-10) codes [19]. The reasons for
hospitalization are coded either as primary
diagnoses (PD; the condition for which the
patient was hospitalized), related diagnoses (RD;
any underlying condition which may have been
related to the PD) or as associated diagnoses
(AD; comorbidities which may affect the course
or cost of hospitalization). In the case of
long-standing condition status, eligible
diseases are identified on a restrictive list
established by the CNAMTS which specifies
the equivalent ICD-10 disease code.
Study Periods
For the description of initiation of insulin
therapy, all new insulin prescriptions
documented in the EGB database between
January 2012 and December 2013 were
considered. A new insulin prescription was
defined as an index insulin prescription during
the reporting period with no such prescription
in the 12 months preceding the index
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prescription. For the description of treatment
persistence, all new index insulin prescriptions
documented in the EGB database between
January 2011 and December 2012 were
considered and insulin prescription followed
longitudinally until December 2013.
Selection of the Study Patients
The study aimed to identify all patients with
diabetes and treated with insulin documented
in the EGB database during the study period. In
a first step, these patients were identified by
three prescription claims for antidiabetic
medication (including insulin products; two
when large packaging was used) within two
consecutive years. Only adult patients C18 years
of age were included. A decision tree was used to
distinguish patients with T1DM from those
with T2DM [20] (Fig. 1). This was based on the
identification of hospitalizations with diabetes
as an identified diagnosis (PD, RD or AD), the
identification of long-standing condition status
for diabetes through the associated ICD-10 code
(E10 for T1DM and E11 for T2DM), as well as
insulin treatment history.
For the purposes of this study, only patients
with T2DM (as defined by the decision tree) and
starting insulin therapy (index insulin
prescription) during the two study periods
described above were retained for analysis.
Patients fulfilling the selection criteria were
divided into three groups: patients delivered
basal insulins only, patients delivered basal and
rapid acting insulins, and patients under other
insulin treatment regimens.
Data Collection
For each participant, data were retrieved from
the EGB database relating to the age and gender
of the patient, antidiabetic medication
prescribed during the study period and during
the year preceding initiation of insulin
treatment and the type of physician
prescribing insulin.
Longitudinal data on prescription of
antidiabetic medication was retrieved covering
the period between the initial insulin
prescription and the end of the study period
(December 31, 2013). Discontinuation of
insulin treatment was defined as the absence
of reimbursement for insulin over a period of
6 months or 1 year after the initiation index
date.
Patients potentially eligible for a short-term
transient insulin therapy were identified as
patients with an hospital admission for a
traumatological (ICD-10 disease classes
S00-T98), infectious (ICD-10 disease classes
A00-B99) or cardiovascular (ICD-10 disease
classes I00-I99) disorder in the 3 months
Paents with 3 andiabec
medicaon prescripons (or 2 
in case of large packaging use)?





ICD-10 code E11 for LSC status















Fig. 1 Decision tree for identifying patients with type 1
(T1DM) and type 2 (T2DM) diabetes. Y yes, N no, LSC
long-standing condition status, ICD international classiﬁ-
cation of disease
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preceding initiation of insulin therapy or
patients treated with corticosteroids (ATC class
H02AB) or antibiotics (ATC classes A0A, J01,
J02, J04 or J05) within 7 days of the initiation of
insulin therapy.
Statistical Analysis
Baseline data at initiation of insulin therapy
are presented as mean values with standard
deviations and median values with range for
continuous variables and as frequency counts
and percentages for categorical variables.
Missing data were not replaced and were
excluded from the descriptive analyses.
Continuous variables were compared between
the three insulin treatment groups using
Student’s t test and categorical variables
using the v2 test. Data on treatment
persistence was analyzed using Kaplan–Meier
survival analysis. A sensitivity analysis was
performed in which patients having
potentially received short-term transient
insulin therapy were excluded. Patients who
left the database, for example, those who died
were censored. However, detailed results
excluding patients who died during the
study period were also provided.
All statistical tests were two-sided and a
probability threshold of 0.05 was taken as
statistically significant. Data analysis was
performed using SAS V9.3 software (SAS
Institute; North Carolina, Unites States).
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies
of human or animal subjects performed by any
of the authors. Access to the EGB database has




Over the 2-year study period (2012 and 2013),
1909 patients in the EGB database were started
on insulin therapy. Between January 1, 2011
and December 31, 2012, 1969 patients were
started on insulin therapy and these patients
were evaluated for persistence of insulin
therapy. Patients were divided into three
groups on the basis of the insulin treatment
regimen prescribed. The distribution of patients
between these groups was similar in the
2011–2012 and 2012–2013 cohorts (Fig. 2),
with around 60% of patients having been
prescribed basal insulin only and around
15.0% a basal-fast acting regimen.
The characteristics of both groups are
presented in Tables 1, 2.
Initiation of Insulin Prescription
Insulin therapy with basal insulin only was
mainly initiated by a general practitioner,
whereas other insulin regimens were
principally initiated by a hospital physician.
During the previous 6 months, 18.9% of all
patients starting an insulin therapy (all schemes)
had been treated with an OAD in monotherapy
and 59.3% with an association of two or more
OADs. The remaining 21.7% of patients had no
previous diabetes treatment documented in the
EGB database. This proportion was three times
higher in the patients starting basal-fast-acting
regimens (40.9%) and other insulin treatment
regimens (32.5%) than in patients initiating
treatment with basal insulin only (13.1%). To
ensure that this absence of previous treatment
was not an artifact due to a gap between
documentation of the last recorded OAD
prescription and the initial insulin
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prescription, the EGB database was searched for
prescription of diabetes medications to these
patients in the 12 months preceding insulin
prescription. This appeared generally not to be
the case, since among the 415 patients who had
no previous diabetes treatment during the
previous 6 months only ten patients (2.4%)
had been prescribed an antidiabetic medication
between twelve and 6 months prior to starting
insulin therapy.
The reimbursement form of the initial
insulin prescription did not include any other
antidiabetic drug in 32.0% of the patients,
although this proportion was considerably
higher in patients starting basal-fast-acting
regimens and other insulin treatment
regimens than in patients initiating treatment
with basal insulin only (Table 1). For the
patients who were also prescribed concomitant
OADs, they received a single OAD therapy
(22.9% of patients) or a dual OAD therapy
(26.0%), or a triple therapy (17.8%) in addition
to insulin. In patients starting a basal-fast-acting
insulin regimen or another insulin treatment
regimen, the use of concomitant OAD with
insulin was less frequent (Table 1). Overall
metformin was associated to insulin in 50.1%
of patients (59.6% in patients starting a basal
only insulin regimen).
Persistence with Insulin Therapy
This analysis was performed in the 1969
patients who initiated insulin therapy between
1st January 2011 and 31st December 2012
(Table 2). Among them, 205 deaths were
observed during the study period (until 31st
December 2013). Excluding deaths, insulin
therapies were discontinued 1 year later in
nearly one third of patients, when
discontinuation was defined as a 6 months
interruption of insulin treatment. If






N = 1180 (61.8%)
Basal/fast-acng regimen
N = 286 (15.0%)
Other insulin regimen
N = 443 (23.2%)






N = 1199 (60.9%)
Basal/fast-acng regimen
N = 259 (13.2%)
Other insulin regimen
N = 511 (26.0%)
Fig. 2 Identiﬁcation of patients with T2DM starting insulin therapy in the EGB database. T2DM type 2 diabetes mellitus,
EGB E´chantillon Ge´ne´raliste de Be´ne´ﬁciaires
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Age (years) N = 1909 N = 1180 N = 286 N = 443
Mean ± SD 65.7 ± 16.0 67.5 ± 14.2 61.8 ± 18.1 63.2 ± 18.4 \0.0001
Median [range] 67 [18; 101] 67 [18; 101] 63.5 [18; 95] 66 [19; 100]
\40 137 (7.2%) 24 (2.0%) 44 (15.4%) 69 (15.6%) \0.0001
40–50 166 (8.7%) 100 (8.5%) 27 (9.4%) 39 (8.8%)
50–60 329 (17.2%) 231 (19.6%) 45 (15.7%) 53 (12.0%)
60–70 466 (24.4%) 299 (25.3%) 67 (23.4%) 100 (22.6%)
70–80 379 (19.9%) 241 (20.4%) 50 (17.5%) 88 (19.9%)
80–90 361 (18.9%) 239 (20.3%) 43 (15.0%) 79 (17.8%)
C90 71 (3.7%) 46 (3.9%) 10 (3.5%) 15 (3.4%)
Gender N = 1818 N = 1177 N = 278 N = 433
Men 1000 (53.0%) 656 (55.7%) 152 (54.7%) 192 (44.3%) 0.0002
Women 888 (47.0%) 521 (44.3%) 126 (45.3%) 241 (55.7%)
Initial insulin prescription
Insulin only 611 (32.0%) 223 (18.9%) 170 (59.4%) 218 (49.2%) \0.0001
Insulin ? 1 OAD 437 (22.9%) 271 (23.0%) 72 (25.2%) 94 (21.2%)
Insulin ? 2 OAD 497 (26.0%) 373 (31.6%) 32 (11.2%) 92 (20.8%)
Insulin ? 3 OAD 340 (17.8%) 294 (24.9%) 10 (3.5%) 36 (8.1%)
Insulin ? C 4 OAD 24 (1.3%) 19 (1.6%) 2 (0.7%) 3 (0.7%)
Metformin 956 (50.1%) 703 (59.6%) 91 (31.8%) 162 (36.6%)
Sulphonylurea 648 (33.9%) 526 (44.6%) 28 (9.8%) 94 (21.2%)
a-Glucosidase inhibitor 49 (2.6%) 42 (3.5%) 2 (0.7%) 5 (1.1%)
Glinides 283 (14.8%) 211 (17.9%) 21 (7.3%) 51 (11.5%)
DPP4i 467 (24.5%) 370 (31.4%) 29 (10.1%) 68 (15.3%)
GLP-1 receptor agonists 146 (7.6%) 125 (10.6%) 3 (1.1%) 18 (4.1%)
Physician prescribing insulin N = 1772 N = 1105 N = 257 N = 410
Hospital physician 798 (45.0%) 381 (34.5%) 177 (68.9%) 240 (58.5%) ND
General practitioner 696 (39.3%) 527 (47.7%) 57 (22.2%) 112 (27.3%)
Community diabetologist 224 (12.6%) 164 (14.8%) 17 (6.6%) 43 (10.5%)
Other community specialist 49 (2.8%) 30 (2.7%) 4 (1.6%) 15 (3.7%)
Diabetes treatment before
the insulin initiationa
N = 1909 N = 1180 N = 286 N = 443
None 415 (21.7%) 154 (13.1%) 117 (40.9%) 144 (32.5%) \0.0001
1 OAD 362 (18.9%) 337 (16.8%) 54 (18.9%) 109 (24.6%)
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discontinuation is set as a 12 months
interruption of insulin treatment, 24.9% of
patients had discontinued insulin therapy
within 1 year after its initiation (excluding
deaths) (Table 3).
Persistence was better in the patients starting
a treatment with a basal insulin only and worse
in those starting other insulin treatment
regimens (Table 3). The median treatment
duration was longest in patients’ prescribed
basal insulin only (17 months) and lowest in
those prescribed another insulin regimen
(9 months). Kaplan–Meier survival curves for
all patients and by insulin treatment group are
provided in Fig. 3. There was limited variation
in the rates of persistence with insulin therapy
according to the specialty of the initial
prescriber (General practitioner vs Diabetes
specialist, data not shown).
Patients discontinuing insulin were younger
(64.7 ± 18.5 years) than those who did not
(67.3 ± 14.3 years; p = 0.0003) and were more
frequently women (54.2% vs 44.3%,
p\0.0001). Interestingly, among patients who
interrupted their insulin treatment during the
first 6 months and were still alive 1 year later,
insulin resumption was observed in 22.3% of
patients, 57.4% were treated with antidiabetic
treatment, and 20.2% did not received any
antidiabetic drug.
A sensitivity analysis was conducted, in
which the patients who had potentially
received short-term transient insulin therapy
were excluded and analyzed separately. This
concerned 901 patients (45.8% of all patients)
who were identified as being hospitalized for a
traumatological, infectious or cardiovascular
disorder in the 3 months preceding initiation
of insulin therapy, or being treated with
corticosteroids or antibiotics within 7 days
prior to the initiation of insulin. Persistence
with insulin therapy was quite similar in
patients who had a reason to receive
short-term transient insulin therapy and those
who did not (Fig. 4).
DISCUSSION
This study was designed to document the
maintenance of insulin therapy in patients
with T2DM after initiation in a representative
sample of the French national insurance claims
database. The main finding was that excluding
deaths and defining discontinuation in a rather
conservative way (at least 12 months without
any reimbursement of insulin therapy) around
25% of patients starting insulin therapy had
discontinued treatment within a year. This high
rate is of concern as the mean age of the












2 OAD 509 (26.7%) 354 (28.9%) 66 (23.1%) 102 (23.1%)
3 OAD 542 (28.4%) 327 (35.9%) 42 (14.7%) 76 (17.2%)
C4 OAD 81 (4.2%) 27 (5.3%) 7 (2.5%) 12 (2.7%)
Characteristics of patients (insulin initiation analysis)
SD standard deviation, OAD oral antidiabetic drug, DPP4i dipeptidyl peptidase inhibitor, GLP glucagon-like peptide, ND not determined
* Student’s t test for continuous values and v2 test for categorical variables
a Over the ﬁrst or the second quarter before the initial insulin prescription
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initiation suggests a need. This observation is
somewhat counter-intuitive because insulin
therapy is usually a late, often delayed, option
in patients with T2DM; indeed, the mean age of
the participants to this study is over 65.
However, the 1-year persistence rates in our
study are consistent with the results from the
claims studies conducted among
North-American patients with diabetes starting
injectable therapy, despite differences in the
health insurance systems. In a study of the
General Electric Centricity electronic medical
record database between November 2004 and
August 2010, Wu et al. [21] found that about a
third of patients (32.9%) initiating an insulin
therapy discontinued (defined as a 90-day gap)
the index insulin within 12 months from
initiation. Wei et al. [15] performed a pooled
analysis of three prescription claims studies
performed in the USA and reported a






Age (years) N = 1969
Mean ± SD 66.4 (16.1)












Insulin only 686 (34.8%)
Insulin ? 1 OAD 486 (24.7%)
Insulin ? 2 OAD 488 (24.8%)
Insulin ? 3 OAD 280 (14.2%)
Insulin ? C 4 OAD 29 (1.5%)
Metformin 896 (45.5%)
Sulphonylurea 651 (33.1%)
a-Glucosidase inhibitor 68 (3.5%)
Glinides 295 (14.9%)
DPP4i 399 (20.3%)
GLP-1 receptor agonists 109 (5.5%)
Physician prescribing insulin N = 1826
Hospital physician 728 (39.9%)
General practitioner 796 (43.6%)














1 OAD 407 (20.7%)
2 OAD 511 (25.9%)
3 OAD 447 (22.7%)
C4 OAD 8 (0.4%)
SD standard deviation, OAD oral antidiabetic drug, DPP4i
dipeptidyl peptidase inhibitor, GLP glucagon-like peptide,
ND not determined
a Over the ﬁrst or the second quarter before the initial
insulin prescription
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persistence rate of 65% at 1 year for patients
starting basal insulin therapy. In another study
from Wang et al. [17] during the 1-year
follow-up, only 54.5% of patients were
persistent to insulin glargine medication.
Other researchers reported a similar rate of
discontinuation in the USA [22, 23] or even
worse: in the study from Cooke et al. [13] the
percentage of patients treated with insulin who
were persistent at 1 year was only 28.7%. In
Japan, 22% of patients discontinued basal
insulin in the year after initiation according to
a reimbursement claim base [24]. In Germany,
the discontinuation rate was also around 20%
and 30% after 1 year with glargine and NPH,
respectively [16]. In this work, in France, a
persistence rate of 75.0% after initiation of
insulin (and 82% when the insulin
scheme was limited to basal insulin use) is
somewhat higher, although it should be noted
that the definition of persistence was not
exactly identical in the aforementioned studies.
The type of physician initiating the insulin
therapy differed according to the treatment
regimens; the general practitioners initiated a
significant number (39%) of the basal insulin
therapies, whereas the majority of the other
regimens were initiated in a hospital setting.
This distribution is likely related to a
combination of reasons: either the severity of
diabetes in hospitalized patients with
comorbidities requires a more intensive
regimen, or the basal-fast-acting insulin
regimen was chosen in an outpatient setting
but its complexity was found to require
initiation during hospitalization.
Unfortunately, it is not possible to assess the
reasons for prescription or the detailed clinical
features of the patient from the data available in
the EGB database. Community-based
endocrinologists or diabetologists appeared to
play a relatively minor role in initiation of
insulin therapy, whatever the treatment
regimen prescribed. With regard to
concomitant therapies, the most frequent
treatment combinations were insulin with
metformin and insulin with metformin and a
sulphonylurea, which are the recommended









Insulin discontinuation deﬁned by a 6 months interruption
Including deaths
After 6 months 24.0 19.0 23.4 37.2
After 12 months 33.4 27.5 35.5 46.9
Excluding deaths
After 6 months 24.6 19.1 24.6 39.3
After 12 months 33.8 28.7 35.4 48.5
Insulin discontinuation deﬁned by a 12 months interruption
Including deaths
After 6 months 18.3 13.1 19.0 30.9
After 12 months 24.9 18.4 17.7 39.6
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combinations in the French guidelines [2].
Nonetheless, around 30% of patients were
apparently prescribed insulin without
concomitant OADs and around 10% insulin
together with three or more OADs. These
combinations are deviations from the latest
French guidelines.
Our study, like every analysis of insurance
claim databases, has several inherent
limitations. First, diagnoses are only directly
documented in the EGB database in case of
hospitalizations and long-standing condition
status, and even in these cases, it is not
possible to ascertain the diagnosis
independently. However, the decision tree
used to ascertain the diagnosis of diabetes on
the basis of the use of drugs has been externally
validated [20]. Second, no information is
available on the clinical status of the patient,
except fatality cases, or on the reasons for which
a given medication was prescribed.
Nevertheless, insurance claims databases have
many advantages for documenting prescription
trends. The EGB database is representative of
insured patients reimbursed for health care in
France and contains exhaustive and reliable
information on all reimbursed prescription
medication. The almost universal coverage of
the French insurance system limits dramatically
missing data and losses of follow-up. Insulin
therapy is only available as a prescription
medication and is not prescribed to a
significant extent to patients without diabetes.
The study does not provide any information
about the reason of early discontinuation of
insulin therapy, i.e., it was not possible to
identify hypoglycemia events, a strong factor
for the patients to stop any of antidiabetic
treatment. Drugs and visits are fully reimbursed
for people with diabetes in France and this
economic aspect has no influence as compare to
Fig. 3 a, b Kaplan–Meier survival curves for the persis-
tence with insulin therapy (discontinuation of insulin
deﬁned by a 6 months period without insulin) in the
newly treated patients. Left all patients, right by treatment
group: blue curve basal insulin only, red curve basal-fast-act-
ing insulin regimen, green curve other insulin treatment
regimens
Fig. 4 Kaplan–Meier survival curves for the persistence
with insulin therapy in the newly treated patients
(discontinuation of insulin deﬁned by a 6 months period
without insulin). Red curve exclusion of patients with a
reason for short-term transient insulin therapy, blue curve
patients with a reason for short-term transient insulin
therapy
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other countries. Further work is needed to
develop answers on this question.
CONCLUSION
Information from the large EGB claimdatabase is
useful to analyze the condition of use of insulin
therapy in patients with diabetes in France. As in
previous studies worldwide, we found that a
significant proportion of patients with T2DM
starting insulin therapy discontinue treatment
within a year. Because very few options are
available for patients failing insulin therapy, it
is important to conduct further realworld studies
aiming at understanding why patients do not
pursue their therapy and identify how to
optimize persistence.
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